Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for adalimumab (compound)


PubChem Substance
Name: adalimumab
PubChem Substance ID: 3820740
Synonyms:
331731-18-1; Humira; Immunoglobulin G1, anti-(human tumor necrosis factor) (human monoclonal D2E7 heavy chain), disulfide with human monoclonal D2E7 light chain, dimer; Adalimumab; Adalimumab [USAN]; D2E7
DrugBank
Identification
Name: adalimumab
Name (isomeric): DB00051
Drug Type: biotech
Synonyms:
Ig gamma-1 chain C region
Brand: Humira, Humira Pen, Humira (Abbott Laboratories)
Category: Immunomodulatory Agents, Antirheumatic Agents
CAS number: 331731-18-1
Pharmacology
Indication: For treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease.
Pharmacology: Used in the treatment of immune system mediated diseases, adalimumab binds specifically to TNF-alpha and blocks its general cytokine effects, thereby reducing TNF-induced inflammation and halting tissue destruction.
Mechanism of Action: Adalimumab binds to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also lyses surface TNF expressing cells in vitro in the presence of complement.
Biotransformation: Most likely removed by opsonization via the reticuloendothelial system.
Half Life: 10-20 days.
Clearance: 12 mL/hr [RA patients with dose 0.25-10 mg/kg]
Affected organisms: Humans and other mammals
Interactions
Drug interaction:
TrastuzumabTrastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.

Targets